Physician profile
Patrick Shane Williams
NPI 1891133344
$5,040.10
in general payments reported to CMS, 2019-2025
42 companies · $809 in 2025
The $809 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $169 · 2021: $292 · 2022: $1,395 · 2023: $800 · 2024: $889 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $673.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Preventric Diagnostics, INC. | $647.22 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $630.59 | 2019-2025 | Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals Lp | $562.65 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $277.21 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $266.58 | 2019-2025 | Vraylar, Ubrelvy |
| Abbott Laboratories | $237.06 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $212.54 | 2019-2025 | Repatha, Otezla, Evenity |
| Gilead Sciences, INC. | $134.72 | 2019-2025 | |
| Bausch Health US, LLC | $121.62 | 2022-2024 | Aplenzin, Wellbutrin |
| Pfizer INC. | $101.67 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.97 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $94.72 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $93.80 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $87.74 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.